How Risky Is Gilead Sciences Inc.?

Image source Getty Images It has been a tough year to be a Gilead Sciences NASDAQ GILD shareholder Fears of incoming competition for the company s hepatitis C virus HCV treatments have been exacerbated by declining sales among its HCV drug based treatments As a result